Synageva Expression Platform

The Synageva Expression Platform (SEP^TM) is a novel, integrated platform of proprietary vectors and protein production, processing and purification systems. The SEP^TM is very competitive with, and in many ways superior to, current expression methods with respect to productivity. It also offers key advantages with regards to cost, scalability, and consistency of end product.

The foundation for the SEP^TM is our proprietary vector technology. Synageva's research team continues to make unprecedented scientific advances such that our vectors presently express protein at ~5 grams/ liter and will be at ~10 grams/ liter later in 2009. A wide variety of proteins have been expressed through the SEP^TM, including monoclonal antibodies, fusion proteins, and cytokines.

The process begins by our team designing constructs whereby the sequence for the human biopharmaceutical protein of interest is inserted alongside a customized, tissue specific promoter. Once this construct is introduced into our clinical production lines, large quantities of the protein of interest are expressed in egg white. Since egg white is a protein-friendly environment with no DNA or lipids, the protein remains very stable. Through robust, highly scalable, fully GMP compliant processes, unpurified bulk is extracted and the human biopharmaceutical protein is purified and fill/finished to ensure high quality biopharmaceuticals are readily available for our clinical programs.

From the time the construct is created in vitro, pre-clinical quantities are available in less than 7 months and commercial scale quantities can be reliably delivered in less than 24 months.

COMPARING EXPRESSION SYSTEMS